Alibaba
BABA
Apple
AAPL
Netflix
NFLX
Tesla
TSLA
Microsoft
MSFT
US Stock MarketDetailed Quotes
IONS Ionis Pharmaceuticals
- 31.720
- +0.230+0.73%
Close Mar 27 16:00 ET
- 31.400
- -0.320-1.01%
Pre 07:22 ET
5.04BMarket Cap-10.43P/E (TTM)
31.790High31.120Low1.15MVolume31.600Open31.490Pre Close36.28MTurnover0.73%Turnover RatioLossP/E (Static)158.96MShares52.34052wk High8.57P/B5.00BFloat Cap30.23052wk Low--Dividend TTM157.59MShs Float86.582Historical High--Div YieldTTM2.13%Amplitude2.500Historical Low31.514Avg Price1Lot Size
Ionis Pharmaceuticals News
UBS Initiates Ionis Pharmaceuticals(IONS.US) With Hold Rating, Announces Target Price $45
Express News | Ionis Expands Partnership With Sobi to Include Olezarsen Commercialization Outside the U.S.
Express News | Ionis Pharmaceuticals Announced That It Has Entered Into A License Agreement Under Which Sobi Receives Exclusive Rights In Countries Outside The U.S., Canada And China To Commercialize Olezarsen As A Potential Treatment For Familial Chylomicronemia...
Is Ionis Pharmaceuticals, Inc. (IONS) a Promising Biotech Stock According to Wall Street Analysts
Hospital Stocks Are Ready to Rebound, Deutsche Bank Says
Proposed Medicaid Cuts Would Devastate Local Economies: Report -- Barrons.com
Ionis Pharmaceuticals Price Target Cut to $45.00/Share From $47.00 by JP Morgan
Ionis Pharmaceuticals Is Maintained at Neutral by JP Morgan
Praxis Precision Medicines to Present on Late-Stage Programs Across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting
J.P. Morgan Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $45
Why Is Ionis Pharmaceuticals (IONS) Up 0.1% Since Last Earnings Report?
Is Ionis Pharmaceuticals (NASDAQ:IONS) Weighed On By Its Debt Load?
Ionis Pharmaceuticals: Strategic Partnerships and Financial Flexibility Drive Buy Rating
Express News | Ionis Pharmaceuticals Inc : Leerink Partners Raises Target Price to $55 From $52
Oppenheimer Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Raises Target Price to $78
William Blair Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating
Ionis Pharmaceuticals (IONS) Receives a Buy From William Blair
Express News | Ionis, Ono Pharmaceutical Enter License Agreement; Ionis To Receive $280M Million Upfront Payment, With Potential To Earn Up To $660M In Milestones
Express News | Ionis and Ono Announce Global License Agreement for Sapablursen in Polycythemia Vera
Ono Enters Into License Agreement With Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera
Market Insights
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
